Osteomyelitis Market Research Report – Forecast to 2027

Osteomyelitis Market Research Report, by Type (Duration, Pathogenesis), by Diagnosis (Blood Tests, Imaging Tests, Bone Biopsy), by Treatment (Antibiotics, Surgery), End-User (Hospital and Clinics, Research Organization) - Forecast Till 2027

ID: MRFR/Pharma/4584-HCR | February 2021 | Region: Global | 90 pages

Osteomyelitis Market Scenario:


The osteomyelitis market is expected to register an approximate CAGR of 6.1% during the forecast period. In the recent years, the prevalence of osteomyelitis has increased, providing favorable backgrounds for the market to grow. According to NCBI in 2016 the total annual occurrence rate of osteomyelitis was 13 per 100,000 (acute osteomyelitis eight and subacute osteomyelitis five per 100,000) globally. Due to the increasing prevalence of osteomyelitis, the market will witness huge demand for treatments, thus, driving the global osteomyelitis market.


Moreover, in 2016, the International Journal of Environmental Research and Public Health stated that the estimated occurrence rate of acute osteomyelitis is about eight cases per 100,000 children/year. According to the U.S. Census Bureau age projection sheet of 2017–2050, the child population is estimated to increase from 73.8 million in 2017 to 79.9 million by 2050. Moreover, according to the World Journal of Diabetes in 2017, diabetic patients are at a higher risk for osteomyelitis. In the recent, years, the prevalence of the osteomyelitis has increased. As per the American Diabetes Association in 2015, ~30.3 million Americans accounting for 9.4% of the population within the region had diabetes. The prevalence of diabetes is estimated to drive the market by increasing the susceptible population.


However, factors such as the limited availability of treatments, risks associated with surgeries, and low healthcare expenditure in the middle and low-income countries are estimated to hinder the market growth during the forecast period.


Segmentation


The global osteomyelitis market is segmented on the basis of type, diagnosis, treatment, and end-user.


The osteomyelitis market, by type, is further segmented by duration, pathogenesis, and others.  The duration segment is sub-segmented into acute and chronic. The pathogenesis segment is sub-segmented into trauma, contiguous spread, and others. By diagnosis, the market is categorized into physical examination, blood tests, imaging tests, bone biopsy, and others. The blood tests segment is sub-segmented into Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR), and C-Reactive Protein (CRP). The imaging segment is sub-segmented into X-rays, Computerized Tomography (CT) scan, and Magnetic Resonance Imaging (MRI). By treatment, the market is segmented into antibiotics and surgery. The antibiotics segment is sub-segmented into ceftriaxone, nafcillin, ceftazidime, and others. On the basis of end-user, the market is segmented into hospitals and clinics, research organizations, diagnostic diseases, and others.


By region, the global osteomyelitis market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas is sub-segmented into North America and South America. The North American region is further segmented into the U.S. and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players:



  • Allergan Plc (Republic of Ireland)

  • CrystalGenomics Inc (South Korea)

  • Debiopharm International SA (Lausanne)

  • Motif Bio Plc (London)

  • Nabriva Therapeutics AG (Dublin)

  • Vyome Biosciences Pvt Ltd (India)

  • F. Hoffmann-La Roche AG (Switzerland)

  • Koninklijke Philips N.V. (Netherlands)

  • General Healthcare (U.S.)

  • Siemens AG (Germany)

  • Toshiba Corporation (Japan)

  • Shimadzu Corporation (Japan)

  • Samsung Electronics Co., Ltd. (South Korea)

  • Neusoft Medical Systems Co., Ltd. (China)

  • Medtronic plc (Ireland)

  • Shenzhen Anke High-tech Co., Ltd. (Hong Kong)


Regional Market Summary


Global Osteomyelitis Market Share (%), by Region, 2017


 Osteomyelitis Market Share


Sources: Journal of Bone and Joint Surgery journal, U.S. Census Bureau, International Journal of Biological Sciences, Indian Brand Equity Foundation, Diabetes UK, Annual Reports, Press Release, White Paper, And Company Presentation


The Americas dominates the global market for osteomyelitis owing to the huge patient population and increasing healthcare expenditure. As per a study published in the International Journal of Biological Sciences in 2015, diabetic patients have higher risks for osteomyelitis. According to the Centers for Disease Control and Prevention in 2017, approximately 30.3 million people, accounting for ~9.4% of the total U.S. population were estimated to suffer from diabetes within the U.S. in 2015.


In 2017, it was estimated that Europe stood second in the global osteomyelitis market. Factors such as the increasing prevalence of osteomyelitis, the presence of developed healthcare industry, and rising government support provide favorable backgrounds for the market to grow. According to the Office for National Statistics in 2015, the government-financed healthcare expenditure accounted for 79.5% of the total spending on healthcare. The government support is estimated to drive the market by enabling the patients’ reach for expensive surgeries.


Asia Pacific was estimated to be the fastest growing region for the global osteomyelitis market in 2017. According to the Indian Brand Equity Foundation in 2017, medical tourism in India is likely to reach a whopping USD 9 billion by 2020 from USD 3 billion in 2015. This increasing medical tourism boosts the Asia Pacific market for osteomyelitis. Moreover, the increasing prevalence of diabetes and an expanding healthcare sector within the region fuel the market within the region.


On the other hand, the Middle East and Africa holds the least share in the global osteomyelitis market. The presence of poor economies, stringent government policies, and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East due to the presence of developed economies such as Kuwait, Qatar, Dubai, and others.


Research Methodology


Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.


Primary Research

Extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.


Secondary Research Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the global osteomyelitis market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.

Segmentation and Key Market Players


Global Osteomyelitis Market, by Diagnosis and Treatment



  • Diagnosis

  • Physical Examination

  • Blood Tests

  • Complete Blood Count (CBC)

  • Erythrocyte Sedimentation Rate (ESR)

  • C-Reactive Protein (CRP)

  • Imaging Tests

  • X-rays

  • Computerized Tomography (CT) Scan

  • Magnetic Resonance Imaging (MRI)

  • Others

  • Bone Biopsy

  • Treatment

  • Antibiotics

  • Ceftriaxone

  • Nafcillin

  • Ceftazidime

  • Others

  • Surgery


Global Osteomyelitis Market, by Pathogenesis



  • Trauma

  • Contiguous Spread

  • Others


Global Osteomyelitis Market, by End-User



  • Hospital and Clinics

  • Research Organization

  • Diagnostic Diseases

  • Diagnostic Centers


Global Osteomyelitis Market, by Region



  • The Americas

  • Europe

  • Asia Pacific

  • The Middle East & Africa


Global Osteomyelitis Market, by Key Players



  • Allergan Plc

  • CrystalGenomics Inc

  • Debiopharm International SA

  • Motif Bio Plc

  • Nabriva Therapeutics AG

  • Hoffmann-La Roche AG

  • Koninklijke Philips N.V.

  • General Healthcare

  • Siemens AG

  • Toshiba Corporation

  • Shimadzu Corporation

  • Samsung Electronics Co., Ltd.

  • Neusoft Medical Systems Co., Ltd.

  • Medtronic plc

  • Shenzhen Anke High-tech Co., Ltd.


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers


 



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


Major diagnostic methods for osteomyelitis include imaging, blood tests, and bone biopsy.

Global Osteomyelitis Market is expected to exhibit a strong 6.1% CAGR over the forecast period till 2027.

The growing prevalence of osteomyelitis is the major driver for the Global Osteomyelitis Market.

The Americas dominate the Global Osteomyelitis Market.

Leading players in the Osteomyelitis Market include Allergan, Siemens, and Toshiba Corporation, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Osteomyelitis Market, by Diagnosis and Treatment

6.1 Introduction

6.2 Diagnosis and Treatment

Market Estimates & Forecast, 2020–2027

6.2.1 Physical Examination

Market Estimates & Forecast, 2020–2027

6.2.2 Blood Tests

Market Estimates & Forecast, 2020–2027

6.2.2.1 Complete Blood Count (CBC)

6.2.2.2 Erythrocyte Sedimentation Rate (ESR)

6.2.2.3 C-Reactive Protein (CRP)

6.2.3 Imaging Tests

Market Estimates & Forecast, 2020–2027

6.2.3.1 X-rays

6.2.3.2 Computerized Tomography (CT) Scan

6.2.3.3 Magnetic Resonance Imaging (MRI)

6.2.3.4 Others

6.2.4 Bone Biopsy

6.2.5 Others

6.3 Treatment

Market Estimates & Forecast, 2020–2027

6.3.1 Antibiotics

Market Estimates & Forecast, 2020–2027

6.3.1.1 Ceftriaxone

6.3.1.2 Nafcillin

6.3.1.3 Ceftazidime

6.3.1.4 Others

6.3.2 Surgery

Market Estimates & Forecast, 2020–2027

Chapter 7. Global Osteomyelitis Market, by Pathogenesis

Market Estimates & Forecast, 2020–2027

7.3.1 Trauma

7.3.2 Contiguous Spread

7.3.3 Others

Chapter 8. Global Osteomyelitis Market, by End-User

8.1 Introduction

8.2 Hospital and Clinics

Market Estimates & Forecast, 2020–2027

8.3 Research Organization

Market Estimates & Forecast, 2020–2027

8.4 Diagnostic Centers

Market Estimates & Forecast, 2020–2027

8.5 Others

Chapter 9. Global Osteomyelitis Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 U.S.

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K.

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Allergan Plc

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 CrystalGenomics Inc

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Debiopharm International SA

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Motif Bio Plc

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Nabriva Therapeutics AG

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 F. Hoffmann-La Roche AG

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Koninklijke Philips N.V.

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 General Healthcare

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Siemens AG

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Toshiba Corporation

11.10.1 Overview

11.10.2 Type Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Shimadzu Corporation

11.11.1 Overview

11.11.2 Type Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.11 Samsung Electronics Co., Ltd.

11.11.1 Overview

11.11.2 Type Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.13 Neusoft Medical Systems Co., Ltd.

11.13.1 Overview

11.13.2 Type Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Medtronic plc

11.14.1 Overview

11.14.2 Type Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Shenzhen Anke High-tech Co., Ltd.

11.15.1 Overview

11.15.2 Type Overview

11.15.3 Financials

11.15.4 Key Developments

11.15.5 SWOT Analysis

11.16 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Osteomyelitis Market Industry Synopsis, 2020–2027

Table 2 Global Osteomyelitis Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Osteomyelitis Market, by Region, 2020–2027, (USD Million)

Table 4 Global Osteomyelitis Market, by Type, 2020–2027, (USD Million)

Table 5 Global Osteomyelitis Market, by Diagnosis and Treatment, 2020–2027, (USD Million)

Table 6 Global Osteomyelitis Market, by End-User, 2020–2027, (USD Million

Table 7 North America Osteomyelitis Market, by Type, 2020–2027, (USD Million)

Table 8 North America Osteomyelitis Market, by Diagnosis and Treatment, 2020–2027, (USD Million)

Table 9 North America Osteomyelitis Market, by End-User, 2020–2027, (USD Million)

Table 10 U.S. Osteomyelitis Market, by Type, 2020–2027, (USD Million)

Table 11 U.S. Osteomyelitis Market, by Diagnosis and Treatment, 2020–2027, (USD Million)

Table 12 U.S. Osteomyelitis Market, by End-User, 2020–2027, (USD Million)

Table 13 Canada Osteomyelitis Market, by Type, 2020–2027, (USD Million)

Table 14 Canada Osteomyelitis Market, by Diagnosis and Treatment, 2020–2027, (USD Million)

Table 15 Canada Osteomyelitis Market, by End-User, 2020–2027, (USD Million)

Table 16 South America Osteomyelitis Market, by Type, 2020–2027, (USD Million)

Table 17 South America Osteomyelitis Market, by Diagnosis and Treatment, 2020–2027, (USD Million)

Table 18 South America Osteomyelitis Market, by End-User, 2020–2027, (USD Million)

Table 19 Europe Osteomyelitis Market, Type, 2020–2027, (USD Million)

Table 20 Europe Osteomyelitis Market, by Diagnosis and Treatment, 2020–2027, (USD Million)

Table 21 Europe Osteomyelitis Market, by End-User, 2020–2027, (USD Million)

Table 22 Western Europe Osteomyelitis Market, by Type, 2020–2027, (USD Million)

Table 23 Western Europe Osteomyelitis Market, by Diagnosis and Treatment, 2020–2027, (USD Million)

Table 24 Western Europe Osteomyelitis Market, by End-User, 2020–2027, (USD Million)

Table 25 Eastern Europe Osteomyelitis Market, by Type, 2020–2027, (USD Million)

Table 26 Eastern Europe Osteomyelitis Market, by Diagnosis and Treatment, 2020–2027, (USD Million)

Table 27 Eastern Europe Osteomyelitis Market, by End-User, 2020–2027, (USD Million)

Table 28 Asia Pacific Osteomyelitis Market, by Type, 2020–2027, (USD Million)

Table 29 Asia Pacific Osteomyelitis Market, by Diagnosis and Treatment, 2020–2027, (USD Million)

Table 30 Asia Pacific Osteomyelitis Market, by End-User, 2020–2027, (USD Million)

Table 31 The Middle East & Africa Osteomyelitis Market, by Type, 2020–2027, (USD Million)

Table 32 The Middle East & Africa Osteomyelitis Market, by Diagnosis and Treatment, 2020–2027, (USD Million)

Table 33 The Middle East & Africa Osteomyelitis Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Osteomyelitis Market

Figure 3 Market Dynamics for Global Osteomyelitis Market

Figure 4 Global Osteomyelitis Market Share, by Type 2020

Figure 5 Global Osteomyelitis Market Share, by Diagnosis and Treatment 2020

Figure 6 Global Osteomyelitis Market Share, by End-User, 2020

Figure 7 Global Osteomyelitis Market Share, by Region, 2020

Figure 8 North America Osteomyelitis Market Share, by Country, 2020

Figure 9 Europe Osteomyelitis Share, by Country, 2020

Figure 10 Asia Pacific Osteomyelitis Market Share, by Country, 2020

Figure 11 The Middle East & Africa Osteomyelitis Market Share, by Country, 2020

Figure 12 Global Osteomyelitis Market: Company Share Analysis, 2020 (%)

Figure 13 Allergan Plc: Key Financials

Figure 14 Allergan Plc: Segmental Revenue

Figure 15 Allergan Plc: Geographical Revenue

Figure 16 CrystalGenomics Inc: Key Financials

Figure 17 CrystalGenomics Inc: Segmental Revenue

Figure 18 CrystalGenomics Inc: Geographical Revenue

Figure 19 Debiopharm International SA: Key Financials

Figure 20 Debiopharm International SA: Segmental Revenue

Figure 21 Debiopharm International SA: Geographical Revenue

Figure 22 Motif Bio Plc: Key Financials

Figure 23 Motif Bio Plc: Segmental Revenue

Figure 24 Motif Bio Plc: Geographical Revenue

Figure 25 Nabriva Therapeutics AG: Key Financials

Figure 26 Nabriva Therapeutics AG: Segmental Revenue

Figure 27 Nabriva Therapeutics AG: Geographical Revenue

Figure 28 Vyome Biosciences Pvt Ltd: Key Financials

Figure 29 Vyome Biosciences Pvt Ltd: Segmental Revenue

Figure 30 Vyome Biosciences Pvt Ltd: Geographical Revenue

Figure 31 F. Hoffmann-La Roche AG: Key Financials

Figure 32 F. Hoffmann-La Roche AG: Segmental Revenue

Figure 33 F. Hoffmann-La Roche AG: Geographical Revenue

Figure 34 Koninklijke Philips N.V.: Key Financials

Figure 35 Koninklijke Philips N.V.: Segmental Revenue

Figure 36 Koninklijke Philips N.V.: Geographical Revenue

Figure 37 General Healthcare: Key Financials

Figure 38 General Healthcare: Segmental Revenue

Figure 39 General Healthcare: Geographical Revenue

Figure 40 Siemens AG: Key Financials

Figure 41 Siemens AG: Segmental Revenue

Figure 42 Siemens AG: Geographical Revenue

Figure 43 Toshiba Corporation: Key Financials

Figure 44 Toshiba Corporation: Segmental Revenue

Figure 45 Toshiba Corporation: Geographical Revenue

Figure 46 Shimadzu Corporation: Key Financials

Figure 47 Shimadzu Corporation: Segmental Revenue

Figure 48 Shimadzu Corporation: Geographical Revenue

Figure 49 Samsung Electronics Co., Ltd.: Key Financials

Figure 50 Samsung Electronics Co., Ltd.: Segmental Revenue

Figure 51 Samsung Electronics Co., Ltd.: Geographical Revenue